We have located links that may give you full text access.
PMM.36 Management of Inflammatory Bowel Disease in Pregnancy.
BACKGROUND: Inflammatory Bowel Disease (IBD) are chronic conditions commonly presenting in the reproductive years with up to 620000 people affected in the UK. Numerous specialist studies and reviews looking at IBD and fertility, IBD medications during pregnancy and breastfeeding, pregnancy outcome in IBD patients exist, but there is no summarising review for clinicians or patients, thus women may not receive consistent advice.
OBJECTIVE: Design and present a management algorithm for clinicians and information leaflet for women with IBD consistent with current literature and available guidelines.
METHOD: Using the European Crohn's Colitis Organisation's (ECCO) guideline on reproduction in inflammatory bowel disease as the baseline, relevant NICE guidelines and other systematic reviews and meta-analyses on the subject of inflammatory bowel disease and reproduction were consulted and reviewed.
RESULTS: Current literature and available guidelines support the consensus that disease remission is the best prognostic indicator of optimal outcome for both mother and baby. Systematic reviews have also highlighted the safety of all commonly used immunosuppressant drugs, with the exception of methotrexate and mycophenolate mofetil.
CONCLUSION: Patients with IBD can have pregnancies comparable to the wider population with normal outcomes. Consistent advice from clinicians and informing IBD patients that they should continue their medications both during breastfeeding may improve compliance and empower the women to get specialist referral where necessary.
OBJECTIVE: Design and present a management algorithm for clinicians and information leaflet for women with IBD consistent with current literature and available guidelines.
METHOD: Using the European Crohn's Colitis Organisation's (ECCO) guideline on reproduction in inflammatory bowel disease as the baseline, relevant NICE guidelines and other systematic reviews and meta-analyses on the subject of inflammatory bowel disease and reproduction were consulted and reviewed.
RESULTS: Current literature and available guidelines support the consensus that disease remission is the best prognostic indicator of optimal outcome for both mother and baby. Systematic reviews have also highlighted the safety of all commonly used immunosuppressant drugs, with the exception of methotrexate and mycophenolate mofetil.
CONCLUSION: Patients with IBD can have pregnancies comparable to the wider population with normal outcomes. Consistent advice from clinicians and informing IBD patients that they should continue their medications both during breastfeeding may improve compliance and empower the women to get specialist referral where necessary.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app